Wordt geladen...
Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies
Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-β (Aβ) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals. Aβ capture by these clinical antibodies is explained here with the...
Bewaard in:
| Gepubliceerd in: | Sci Rep |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4549621/ https://ncbi.nlm.nih.gov/pubmed/25880481 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep09649 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|